Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 10, 2023
Share
Kim Forest Enterprise Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 100.91 million compared to TWD 137.44 million a year ago. Net loss was TWD 26.35 million compared to TWD 11.59 million a year ago. Basic loss per share from continuing operations was TWD 0.57 compared to TWD 0.25 a year ago. Diluted loss per share from continuing operations was TWD 0.57 compared to TWD 0.25 a year ago.
For the nine months, sales was TWD 284.38 million compared to TWD 566.77 million a year ago. Net loss was TWD 64.46 million compared to net income of TWD 76.42 million a year ago. Basic loss per share from continuing operations was TWD 1.4 compared to basic earnings per share from continuing operations of TWD 1.66 a year ago. Diluted loss per share from continuing operations was TWD 1.4 compared to diluted earnings per share from continuing operations of TWD 1.64 a year ago.
KIM FOREST ENTERPRISE CO., LTD. is a Taiwan-based company mainly engaged in sale of biomedical products and provision of genetic testing and analysis services. The Company operates through two segments. The Biomedical Experiment Products segment is engaged in provision of laboratory equipment, reagents, supplies and equipment maintenance services. Main products include filter type microplate spectrophotometer, polymerase chain reaction (PCR) molecular biology experiment related equipment and reagents, equipment and reagents for separating cell, protein and nucleic acids, rapid DNA detection reagent and others. The Biotechnology and Genetic Testing segment is engaged in provision of whole genome sequencing (WGS) and whole exome sequencing(WES) tumor analysis services, RNA sequencing analysis, and new drug development system and check services.
KIM FOREST ENTERPRISE CO., LTD. 
